The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung transplant recipients, to explore its covariates, and to propose an individualized dosing regimen. Ganciclovir was administered according to the protocol in a standardized intravenous dose of 5 mg/kg twice daily. Serum ganciclovir concentrations were monitored as a trough and at 3 and 5 h after dosing. Individual ganciclovir pharmacokinetic parameters were calculated in a two-compartmental pharmacokinetic model, while regression models were used to explore the covariates. Optimal loading and maintenance doses were calculated for each patient. In lung transplant recipients (n = 40), the median (IQR) ganciclovir total volume of distribution and clearance values were 0.65 (0.52-0.73) L/kg and 0.088 (0.059-0.118) L/h/kg, respectively. We observed medium-to-high inter-individual but negligible intra-individual variability in ganciclovir pharmacokinetics. The volume of distribution of ganciclovir was best predicted by height, while clearance was predicted by glomerular filtration rate. Bodyweight-normalized clearance was significantly higher in patients with cystic fibrosis, while distribution half-life was reduced in this subgroup. On the basis of the observed relationships, practical nomograms for individualized ganciclovir dosing were proposed. The dosing of ganciclovir in patients with cystic fibrosis requires special caution, as their daily maintenance dose should be increased by approximately 50%.

Department of Medical Chemistry and Clinical Biochemistry 2nd Faculty of Medicine Charles University Prague and Motol University Hospital 150 06 Prague Czech Republic

Department of Medical Microbiology 2nd Faculty of Medicine Charles University Prague and Motol University Hospital 150 06 Prague Czech Republic

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague 128 00 Prague Czech Republic

Prague Lung Transplant Program 3rd Department of Surgery 1st Faculty of Medicine Charles University Prague and Motol University Hospital 150 06 Prague Czech Republic

See more in PubMed

Hubacek P., Virgili A., Ward K.N., Pohlreich D., Keslova P., Goldova B., Markova M., Zajac M., Cinek O., Nacheva E.P., et al. HHV-6 DNA throughout the tissues of two stem cell transplant patients with chromosomally integrated HHV-6 and fatal CMV pneumonitis. Br. J. Haematol. 2009;145:394–398. doi: 10.1111/j.1365-2141.2009.07622.x. PubMed DOI

Kurihara C., Fernandez R., Safaeinili N., Akbarpour M., Wu Q., Budinger G.R.S., Bharat A. Long-Term Impact of Cytomegalovirus Serologic Status on Lung Transplantation in the United States. Ann. Thorac. Surg. 2019;107:1046–1052. doi: 10.1016/j.athoracsur.2018.10.034. PubMed DOI PMC

Kotton C.N., Kumar D., Caliendo A.M., Huprikar S., Chou S., Danziger-Isakov L., Humar A., The Transplantation Society International CMV Consensus Group The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102:900–931. PubMed

Ho S.A., Slavin M., Roberts J.A., Yong M. Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients—The role of therapeutic drug monitoring. Expert Rev. Anti-Infect. Ther. 2021;19:707–718. doi: 10.1080/14787210.2021.1851193. PubMed DOI

Perrottet N., Decosterd L.A., Meylan P., Pascual M., Biollaz J., Buclin T. Valganciclovir in adult solid organ transplant recipients: Pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin. Pharmacokinet. 2009;48:399–418. doi: 10.2165/00003088-200948060-00006. PubMed DOI

Gilbert C., Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 2005;49:873–883. doi: 10.1128/AAC.49.3.873-883.2005. PubMed DOI PMC

Razonable R.R. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients. Infect. Dis. Clin. N. Am. 2013;27:317–342. doi: 10.1016/j.idc.2013.02.005. PubMed DOI

Davis C.L., Springmeyer S., Gmerek B.J. Central nervous system side effects of ganciclovir. N. Engl. J. Med. 1990;322:933–934. PubMed

Chambers D.C., Zuckermann A., Cherikh W.S., Harhay M.O., Hayes D., Jr., Hsich E., Khush K.K., Potena L., Sadavarte A., Singh T.P., et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report—2020; focus on deceased donor characteristics. J. Heart Lung Transplant. 2020;39:1016–1027. doi: 10.1016/j.healun.2020.07.009. PubMed DOI PMC

Snell G.I., Kotsimbos T.C., Levvey B.J., Skiba M., Rutherford D.M., Kong D.C., Williams T.J., Krum H. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. J. Antimicrob. Chemother. 2000;45:511–516. doi: 10.1093/jac/45.4.511. PubMed DOI

Crumpacker C.S. Ganciclovir. N. Engl. J. Med. 1996;335:721–729. doi: 10.1056/NEJM199609053351007. PubMed DOI

Faulds D., Heel R.C. Ganciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39:597–638. doi: 10.2165/00003495-199039040-00008. PubMed DOI

Du Bois D., Du Bois E.F. A formula to estimate the approximate surface area if height and weight be known. Nutrition. 1989;5 PubMed

Inker L.A., Schmid C.H., Tighiouart H., Eckfeldt J.H., Feldman H.I., Greene T., Kusek J.W., Manzi J., Van Lente F., Zhang Y.L., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 2012;367:20–29. doi: 10.1056/NEJMoa1114248. PubMed DOI PMC

Garrow J.S. Quetelet index as indicator of obesity. Lancet. 1986;1:1219. doi: 10.1016/S0140-6736(86)91207-9. PubMed DOI

U.S. Department of Health and Human Services, Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation. U.S. [(accessed on 3 February 2022)];2018 Available online: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.

Sommadossi J.P., Bevan R., Ling T., Lee F., Mastre B., Chaplin M.D., Nerenberg C., Koretz S., Buhles W.C., Jr. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev. Infect. Dis. 1988;10((Suppl. 3)):S507–S514. doi: 10.1093/clinids/10.Supplement_3.S507. PubMed DOI

Bonett D.G., Price R.M. Statistical inference for a linear function of medians: Confidence intervals, hypothesis testing, and sample size requirements. Psychol. Methods. 2002;7:370–383. doi: 10.1037/1082-989X.7.3.370. PubMed DOI

Sima M., Pokorna P., Hronova K., Slanar O. Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. Physiol. Res. 2015;64:S513–S519. doi: 10.33549/physiolres.933213. PubMed DOI

Ritchie B.M., Barreto J.N., Barreto E.F., Crow S.A., Dierkhising R.A., Jannetto P.J., Tosh P.K., Razonable R.R. Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety. Antimicrob. Agents Chemother. 2019;63:e01855-18. doi: 10.1128/AAC.01855-18. PubMed DOI PMC

Trachuk P., Bartash R., Abbasi M., Keene A. Infectious Complications in Lung Transplant Recipients. Lung. 2020;198:879–887. doi: 10.1007/s00408-020-00403-9. PubMed DOI PMC

Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 2010;23:689–712. doi: 10.1128/CMR.00009-10. PubMed DOI PMC

Stockmann C., Roberts J.K., Knackstedt E.D., Spigarelli M.G., Sherwin C.M. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin. Drug Metab. Toxicol. 2015;11:205–219. doi: 10.1517/17425255.2015.988139. PubMed DOI

Galar A., Valerio M., Catalan P., Garcia-Gonzalez X., Burillo A., Fernandez-Cruz A., Zatarain E., Sousa-Casasnovas I., Anaya F., Rodriguez-Ferrero M.L., et al. Valganciclovir-Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship. Antibiotics. 2021;10:77. PubMed PMC

Martson A.G., Edwina A.E., Burgerhof J.G.M., Berger S.P., de Joode A., Damman K., Verschuuren E.A.M., Blokzijl H., Bakker M., Span L.F., et al. Ganciclovir therapeutic drug monitoring in transplant recipients. J. Antimicrob. Chemother. 2021;76:2356–2363. doi: 10.1093/jac/dkab195. PubMed DOI PMC

De Sutter P.J., Gasthuys E., Van Braeckel E., Schelstraete P., Van Biervliet S., Van Bocxlaer J., Vermeulen A. Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019. Clin. Pharmacokinet. 2020;59:1551–1573. doi: 10.1007/s40262-020-00932-9. PubMed DOI

Jouret F., Bernard A., Hermans C., Dom G., Terryn S., Leal T., Lebecque P., Cassiman J.J., Scholte B.J., de Jonge H.R., et al. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J. Am. Soc. Nephrol. 2007;18:707–718. doi: 10.1681/ASN.2006030269. PubMed DOI

Scott J.C., Partovi N., Ensom M.H. Ganciclovir in solid organ transplant recipients: Is there a role for clinical pharmacokinetic monitoring? Ther. Drug Monit. 2004;26:68–77. doi: 10.1097/00007691-200402000-00014. PubMed DOI

Lefeuvre S., Chevalier P., Charpentier C., Zekkour R., Havard L., Benammar M., Amrein C., Boussaud V., Lillo-Le Louet A., Guillemain R., et al. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: Retrospective study of efficacy, safety, and drug exposure. Transpl. Infect. Dis. 2010;12:213–219. doi: 10.1111/j.1399-3062.2010.00491.x. PubMed DOI

Murray B.M. Management of cytomegalovirus infection in solid-organ transplant recipients. Immunol. Investig. 1997;26:243–255. doi: 10.3109/08820139709048930. PubMed DOI

Palacio-Lacambra M.E., Comas-Reixach I., Blanco-Grau A., Sune-Negre J.M., Segarra-Medrano A., Montoro-Ronsano J.B. Comparison of the Cockcroft-Gault, MDRD and CKD-EPI equations for estimating ganciclovir clearance. Br. J. Clin. Pharmacol. 2018;84:2120–2128. doi: 10.1111/bcp.13647. PubMed DOI PMC

Sima M., Hartinger J., Cikankova T., Slanar O. Estimation of once-daily amikacin dose in critically ill adults. J. Chemother. 2018;30:37–43. doi: 10.1080/1120009X.2017.1376818. PubMed DOI

Sima M., Hartinger J., Stenglova Netikova I., Slanar O. Creatinine Clearance Estimations for Vancomycin Maintenance Dose Adjustments. Am. J. Ther. 2018;25:e602–e604. doi: 10.1097/MJT.0000000000000616. PubMed DOI

Wiltshire H., Paya C.V., Pescovitz M.D., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005;79:1477–1483. doi: 10.1097/01.TP.0000164512.99703.AD. PubMed DOI

Rousseau A., Monchaud C., Debord J., Vervier I., Estenne M., Thiry P., Marquet P. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther. Drug Monit. 2003;25:28–35. doi: 10.1097/00007691-200302000-00004. PubMed DOI

The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model